Schering's quazepam (Dormalin)
Schering's quazepam (Dormalin): Licensed to Ivax subsidiary Baker Cummins Pharmaceuticals for manufacturing and marketing in the U.S. and Canada. Schering obtained approval for the sedative/hypnotic in late 1985, but never brought the product to market in the U.S. Baker Cummins said it will begin marketing the drug within the next several months. Schering has obtained an exclusive worldwide license from Baker Cummins for an undisclosed sustained release antibiotic that Baker is currently developing.
You may also be interested in...
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.